2019
DOI: 10.1039/c9ra03579f
|View full text |Cite
|
Sign up to set email alerts
|

The secondary metabolites of rare actinomycetes: chemistry and bioactivity

Abstract: A detailed introduction to the structures and bioactivities of secondary metabolites from rare actinomycetes is made.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
36
0
1

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 60 publications
(38 citation statements)
references
References 105 publications
1
36
0
1
Order By: Relevance
“…It is generally accepted that rare actinobacterial genera possess more potential in terms of secondary metabolites novelty ( Schorn et al, 2016 ; Bundale et al, 2019 ; Ding et al, 2019 ). Thus, exploration of bioactive chemicals from rare actinobacterial strains will be more promising and efficient.…”
Section: Discussionmentioning
confidence: 99%
“…It is generally accepted that rare actinobacterial genera possess more potential in terms of secondary metabolites novelty ( Schorn et al, 2016 ; Bundale et al, 2019 ; Ding et al, 2019 ). Thus, exploration of bioactive chemicals from rare actinobacterial strains will be more promising and efficient.…”
Section: Discussionmentioning
confidence: 99%
“…More attentions have been diverted to microorganisms that are previously inadequately assessed or from underexplored environments. The rare actinomycetes are referred to the actinomycetes strains less frequently obtained than that of commonly isolated Streptomyces spp., even though they might not actually be uncommon in the environment . Among rare actinomycete, the genera Micromonospora was observed to produce the highest numbers of natural products …”
Section: Introductionmentioning
confidence: 99%
“…In the past decades, actinobacteria, particularly from the genus Streptomyces, have been reported to produce about two thirds of the naturally derived antibiotics in current clinical use, as well as many anticancer compounds [2]. While Streptomyces species appear to have been exhaustively explored [3,4], other genera belonging to the so-called "rare actinobacteria" may still serve as promising sources for novel biologically active secondary metabolites [4][5][6][7]. One of these genera is Nonomuraea, which has recently been reported to produce several new biologically active compounds such as the antimicrobial hypogeamycins B-D [8], nonomuric acid and 3-hydroxy deoxydaunorubicinol aglycone [9], the cytotoxic hypogeamycin A [8], and karamomycins [10].…”
Section: Introductionmentioning
confidence: 99%